arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Sunshine Biopharma Inc.

SBFM
$2.85 ▲ +0.16 (+5.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sunshine Biopharma Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.9M
Dividend Yield —
Revenue Growth -1.6% ↗
Op. Margin -17.4% →
ROIC -5.9% ↗
FCF / Share $-0.68 ↘
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.26M
↓ -1.6% —
Net Income Profit after all expenses
$-1.56M
↑ +11.7% —
Operating Margin Operating profit as % of sales
-17.4%
↓ -0.9% 11th
FCF / Share Free cash flow per share
$-0.68
↓ -60.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns
25
Cash Quality ↑
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 17 years · 67 quarters